HOME >> BIOLOGY >> NEWS
Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ

CRAIGAVON, NORTHERN IRELAND, 8 Aug 2007 Today Almac Diagnostics announced a major study analysing ductal carcinoma in situ tissue samples using its novel Breast Cancer DSA microarray. DSA research tools focus on the transcriptome of an individual disease, in this case breast cancer, and contain significant additional data, relevant to the disease of interest that is not available on other generic microarrays. The study will be conducted in collaboration with Prof Adrian Harris, Cancer Research UK and Professor of Medical Oncology at the University of Oxford.

Our novel technology is helping researchers to reduce discovery timelines, accelerate the validation process and ultimately deliver clinical applications in this disease setting. said Paul Harkin, BSc, PhD, Professor of Molecular Oncology at the Centre for Cancer Research and Cell Biology, Queens University, Belfast and MD and President of Almac Diagnostics.

This particular study aims to generate a gene signature to identify the subset of DCIS patients who are likely to suffer a recurrence, he added.

The study will use paraffin embedded samples and is due to commence in the coming weeks. Tissue samples will be analysed using the Breast Cancer DSA research tool. An Almac bioinformatics team will interrogate the resulting data to identify any potential signature.

Our research will use the Breast Cancer DSA microarray to examine the transcriptome of ductal carcinoma in situ at a greater level of specificity generating additional information that will help us draw meaningful conclusions from our data. Eventually we hope to develop a gene expression signature that will inform clinical treatment strategies" said Prof Adrian Harris, Cancer Research UK Professor of Medical Oncology at the University of Oxford and Principal Investigator on the study.

In some cases, the treatment for DCIS is total mastectomy as it is curative in nearly all patients1. However, t
'"/>

Contact: Vanessa Leon
vanessa.leon@edelman.com
44-207-344-1344
Edelman Public Relations
8-Aug-2007


Page: 1 2

Related biology news :

1. Almac Diagnostics attends pre-IDE meeting with FDA
2. Almac Diagnostics announces pioneering genetic research on colorectal pre-malignancies
3. ESA announces 2007 award recipients
4. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
5. Conservation Leadership Program announces 2007 awardees
6. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
7. Revolutionary global environment fund announces $50M expansion
8. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
9. Cell Press announces new partnership with the American Society of Human Genetics
10. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML
11. Minister Lunn announces $39.6M for next phase of mountain pine beetle response

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2018)... (PRWEB) , ... August 20, ... ... of advanced software solutions for biopharma R&D, today announced that Seattle-based ... preferred bioinformatics solution provider. Aptevo will use the Genedata Biologics ® ...
(Date:8/17/2018)... (PRWEB) , ... August 16, ... ... acquisition of NXT-Dx, an established epigenetics service provider based in Gent, Belgium. ... of targeted DNA methylation assays using pyrosequencing or Next-Generation Sequencing and Illumina’s ...
(Date:8/17/2018)... Colo. (PRWEB) , ... August 16, 2018 , ... Today, ... muscular dystrophy (FSHD), announced that its Colorado Chapter will be holding its 3rd ... for September 8th at the Philip S. Miller Park, advocates for public awareness and ...
Breaking Biology News(10 mins):
(Date:8/29/2018)... GARDEN CITY, N.Y. (PRWEB) , ... August 28, ... ... , a leading online retailer of contact lenses, has been ranked in 1138th ... nation’s fastest growing private companies. , The list represents the most successful ...
(Date:8/26/2018)... ... August 24, 2018 , ... ExoCoBio Inc., ... dramatically relieves atopic dermatitis and inhibits a variety of inflammatory targets in the ... the symptoms of mice having severe atopic dermatitis were significantly improved after administration ...
(Date:8/17/2018)... ... August 16, 2018 , ... The opening of the new Titusville facility marks ... in 2016. Chemko had a well established local presence, servicing the Space Coast since ... such as the ongoing work at the Mobile Launch Platform (MLP) in support of ...
(Date:8/14/2018)... ... August 14, 2018 , ... Buprenorphine (BUP) is a ... is often prescribed as a sublingual co-formulation with the opioid antagonist naloxone (NXO) ... will learn from a review of the pharmacokinetics of BUP, NBP, and NXO ...
Breaking Biology Technology:
Cached News: